Abstract: The current application relates to pyronaridine or 6-chloro-2-methoxyacridine analogs having binding affinity for the ERCC1-XPF hetero-dimerization interface. The compounds can be used for targeting DNA repair in tumor cells via ER-CC1-XPF inhibition, therefore improving the therapeutic benefit of irradiation or other cancer treatment, or reducing the dosage and adverse effects associated with such treatment.

Abstract: Described herein are bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their application in multimodal theranostic management of hypoxia diseases including cancer.

Abstract: There is described herein imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase.

Abstract: Described herein are bioreductively-activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their application in multimodal theranostic management of hypoxia diseases including cancer.

Abstract: Described herein are markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy. A compound comprising bio-reductively activated (BA) arm, linker arm and a mapping click wherein BA contains one for more of substituted or unsubstituted 2/4/5-substituted nitroimidazoles, or substituted benzotriazene-1,4-dioxides, or substituted 1,2,3/1,2,4-triazoles, or substituted 1,4-benzoquinones, or a combination of two homo-or hetero BA moieties, wherein linker arm contains C1-16 alkane, alkene, alkyne, alicyclic or aromatic linkers with or without hetero atoms as in ethers, amine, esters, acid, amides, 5 and 6 membered sugar sings with the substitution as described above, both monosaccharides and disaccharides, wherein mapping click contains one of substituted or unsubstituted —N3-, CN, SCN, substituted alkynes for click chemistry.

Abstract: There is described herein imidopiperidine compounds as inhibitors of human polynucleotide kinase phosphatase.

Abstract: There is described herein compounds, compositions and methods for inducing synthetic lethality in a cancer cell(s).

Abstract: The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions.

Abstract: There is described herein compounds, compositions and methods for inducing synthetic lethality in a cancer cell(s).

Abstract: The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions.

Abstract: There is described herein compounds, compositions and methods for inducing synthetic lethality in a cancer cell(s).

Abstract: The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions.

Abstract: There is described herein compounds, compositions and methods for inducing synthetic lethality in a cancer cell(s).

Abstract: The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions.

Abstract: The present invention provides methods for the detection and quantitation of any modification of interest in any nucleic acid sequence. In particular, the invention provides methods for detecting and quantitating low levels of modifications of interest in DNA sequences. The methods of the invention take advantage of combining the use of nucleic acid sequence modification-specific molecules which are specific for DNA modifications, of fluorescently labelled proteins which are specific for the nucleic acid sequence modification-specific molecules, of capillary electrophoresis and of laser-induced fluorescence. The methods of the invention are useful for identifying and detecting exposure to carcinogens, in early risk assessment for cancer, and in monitoring of cancer therapy.